CordenPharma Expands GLP-1 Manufacturing Footprint in U.S. and Europe with $980M Commitment

By /

To help keep pace with the demand for GLP-1 therapies, CordenPharma has announced a sizeable $980 million investment in its U.S. and European sites.

Scroll to Top